- Home
- CVRX vs ENLV Comparison
CVRX vs ENLV Comparison
Compare CVRX & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CVRX | ENLV |
|---|---|---|
| Founded | 2000 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.8M | 149.0M |
| IPO Year | 2021 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CVRX | ENLV |
|---|---|---|
| Price | $5.58 | $2.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $10.50 | ★ $20.00 |
| AVG Volume (30 Days) | 212.1K | ★ 287.7K |
| Earning Date | 05-11-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $56,651,000.00 | N/A |
| Revenue This Year | $17.17 | N/A |
| Revenue Next Year | $17.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.45 | N/A |
| 52 Week Low | $4.37 | $0.43 |
| 52 Week High | $11.30 | $7.64 |
Technical Indicators
Market Signals| Indicator | CVRX | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 54.76 | 42.81 |
| Support Level | $5.05 | $0.77 |
| Resistance Level | $5.96 | $7.64 |
| Average True Range (ATR) | 0.31 | 0.43 |
| MACD | 0.08 | -0.38 |
| Stochastic Oscillator | 83.20 | 12.95 |
Price Performance
Historical ComparisonAbout CVRX CVRx Inc.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.